william wierda | ibrutinib and venetoclax combination for first-line cll: captivate phase ii trial
Published 6 years ago • 948 plays • Length 2:28Download video MP4
Download video MP3
Similar videos
-
1:16
dr. wierda on ibrutinib plus venetoclax in cll
-
6:39
ibrutinib venetoclax for chronic lymphocytic leukemia (cll) treatment - dr. bill wierda ash 2022
-
4:46
support shown for fixed-duration combination ibrutinib venetoclax for cll patients
-
2:18
first-line ibrutinib and venetoclax in cll
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
5:29
long term follow-up with ibrutinib venetoclax to treat chronic lymphocytic leukemia
-
8:57
venetoclax combined with obinutuzumab for untreated cll (chronic lymphocytic leukemia)
-
5:51
venetoclax in chronic lymphocytic leukemia
-
1:38
dr. william g. wierda on role for ibrutinib in frontline cll
-
2:21
captivate: ibrutinib and venetoclax in cll
-
7:39
ash 2020: dr. wierda discusses phase 2 captivate study data
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
2:37
combination therapy for cll in the captivate trial
-
11:23
captivate: fixed-duration first-line treatment with ibrutinib plus venetoclax for cll/sll
-
3:01
ibrutinib venetoclax for cll
-
5:54
updates from captivate: ibrutinib and venetoclax for cll
-
1:40
captivate and beyond: combination therapies for cll
-
6:14
ibrutinib plus venetoclax for treatment of cll (chronic lymphocytic leukemia) - asco 2022
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
4:04
ibrutinib plus venetoclax for the first-line treatment of cll/sll: results from the captivate study
-
1:23
captivate: fixed-duration ibrutinib plus venetoclax in patients with cll/sll
-
4:45
frontline ibrutinib venetoclax in cll: results from a fixed duration cohort of the captivate study